P7C3 Compounds as Targeted Mitochondrial Therapeutics for Brain Disorders.
CNS Neurosci TherSep 1, 2026
Yajing Chen, Xiaohuan Du, Fang Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluates P7C3 compounds, which activate NAMPT and enhance NAD+ levels, across various neurological disorders. The review synthesizes their mechanisms and preclinical efficacy in conditions like Alzheimer's and Parkinson's disease. Notably, P7C3 compounds improve mitochondrial function and reduce oxidative stress, highlighting their potential as neuroprotective agents.
Key findings
- P7C3 compounds elevate intracellular NAD+ levels and engage SIRT1 and SIRT3 deacetylase cascades.
- They enhance mitochondrial quality control and attenuate oxidative stress.
- Preclinical studies show efficacy in Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
- Neuroprotective effects occur independently of disease-specific aggregates.
Why it matters
Understanding the mechanisms and therapeutic potential of P7C3 compounds could inform future treatment strategies for various neurological disorders, particularly those characterized by mitochondrial dysfunction and oxidative stress.